In conclusion, a protocol is presented for a planned study that seeks to describe the safety and effectiveness of erlotinib and gefitinib during the first decade of their routine clinical use in NZ for treating EGFR mutation–positive lung cancer in a national whole-of-patient-population retrospective cohort. This evidence concerns the gene EGFR and lung cancer.